share_log

EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24

EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24

EF Hutton發起買入評級對CARISMA Therapeutics進行覆蓋,宣佈股價目標爲24美元
Benzinga ·  2024/10/30 08:15  · 評級/大行評級

EF Hutton analyst Jason Kolbert initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Target of $24.

EF Hutton的分析師Jason Kolbert對CARISMA Therapeutics(納斯達克股票代碼:CARM)發起覆蓋,給予買入評級,並宣佈目標價爲$24。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論